m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00581)
Target Name Transgelin (SM22alpha)
Synonyms
22 kDa actin-binding protein; Protein WS3-10; Smooth muscle protein 22-alpha; SM22-alpha
    Click to Show/Hide
Gene Name SM22alpha
Chromosomal Location 11q23.3
Family Calponin family
Function
Actin cross-linking/gelling protein (By similarity). Involved in calcium interactions and contractile properties of the cell that may contribute to replicative senescence.
    Click to Show/Hide
Gene ID 6876
Uniprot ID
TAGL_HUMAN
HGNC ID
HGNC:11553
Ensembl Gene ID
ENSG00000149591
KEGG ID
hsa:6876
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
SM22alpha can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Fat mass and obesity-associated protein (FTO) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by FTO
Cell Line TPC_1 cell line Homo sapiens
Treatment: FTO overexpression TPC_1 cells
Control: TPC_1 cells
 GSE199206
Regulation
logFC: 6.14E-01
p-value: 1.66E-07
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary FTO knockdown elevated Transgelin (SM22alpha) expression and m6A-binding protein IGF2BP2 enhanced SM22alpha mRNA stability by recognizing and binding to m6A methylation modified mRNA. m6A methylation-mediated elevation of SM22alpha restrained VSMC proliferation and migration and ameliorated intimal hyperplasia in T2DM.
Target Regulation Down regulation
Responsed Disease Type 2 diabetes mellitus ICD-11: 5A11
 Disease Info 
In-vitro Model VSMC (Human aortic vascular smooth muscle cells)
Type 2 diabetes mellitus [ICD-11: 5A11]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary FTO knockdown elevated Transgelin (SM22alpha) expression and m6A-binding protein IGF2BP2 enhanced SM22alpha mRNA stability by recognizing and binding to m6A methylation modified mRNA. m6A methylation-mediated elevation of SM22alpha restrained VSMC proliferation and migration and ameliorated intimal hyperplasia in T2DM.
Responsed Disease Type 2 diabetes mellitus [ICD-11: 5A11]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Down regulation
In-vitro Model VSMC (Human aortic vascular smooth muscle cells)
References
Ref 1 M(6)A methylation-mediated elevation of SM22Alpha?inhibits the proliferation and migration of?vascular smooth muscle cells and ameliorates?intimal hyperplasia in type 2 diabetes mellitus. Biol Chem. 2021 Dec 7;403(3):317-329. doi: 10.1515/hsz-2021-0296. Print 2022 Feb 23.